Cargando…
Untreated PKU Patients without Intellectual Disability: What Do They Teach Us?
Phenylketonuria (PKU) management is aimed at preventing neurocognitive and psychosocial dysfunction by keeping plasma phenylalanine concentrations within the recommended target range. It can be questioned, however, whether universal plasma phenylalanine target levels would result in optimal neurocog...
Autores principales: | , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6893397/ https://www.ncbi.nlm.nih.gov/pubmed/31731404 http://dx.doi.org/10.3390/nu11112572 |
_version_ | 1783476189185179648 |
---|---|
author | van Vliet, Danique van Wegberg, Annemiek M.J. Ahring, Kirsten Bik-Multanowski, Miroslaw Casas, Kari Didycz, Bozena Djordjevic, Maja Hertecant, Jozef L. Leuzzi, Vincenzo Mathisen, Per Nardecchia, Francesca Powell, Kimberly K. Rutsch, Frank Stojiljkovic, Maja Trefz, Fritz K. Usurelu, Natalia Wilson, Callum van Karnebeek, Clara D. Hanley, William B. van Spronsen, Francjan J. |
author_facet | van Vliet, Danique van Wegberg, Annemiek M.J. Ahring, Kirsten Bik-Multanowski, Miroslaw Casas, Kari Didycz, Bozena Djordjevic, Maja Hertecant, Jozef L. Leuzzi, Vincenzo Mathisen, Per Nardecchia, Francesca Powell, Kimberly K. Rutsch, Frank Stojiljkovic, Maja Trefz, Fritz K. Usurelu, Natalia Wilson, Callum van Karnebeek, Clara D. Hanley, William B. van Spronsen, Francjan J. |
author_sort | van Vliet, Danique |
collection | PubMed |
description | Phenylketonuria (PKU) management is aimed at preventing neurocognitive and psychosocial dysfunction by keeping plasma phenylalanine concentrations within the recommended target range. It can be questioned, however, whether universal plasma phenylalanine target levels would result in optimal neurocognitive outcomes for all patients, as similar plasma phenylalanine concentrations do not seem to have the same consequences to the brain for each PKU individual. To better understand the inter-individual differences in brain vulnerability to high plasma phenylalanine concentrations, we aimed to identify untreated and/or late-diagnosed PKU patients with near-normal outcome, despite high plasma phenylalanine concentrations, who are still alive. In total, we identified 16 such cases. While intellectual functioning in these patients was relatively unaffected, they often did present other neurological, psychological, and behavioral problems. Thereby, these “unusual” PKU patients show that the classical symptomatology of untreated or late-treated PKU may have to be rewritten. Moreover, these cases show that a lack of intellectual dysfunction despite high plasma phenylalanine concentrations does not necessarily imply that these high phenylalanine concentrations have not been toxic to the brain. Also, these cases may suggest that different mechanisms are involved in PKU pathophysiology, of which the relative importance seems to differ between patients and possibly also with increasing age. Further research should aim to better distinguish PKU patients with respect to their cerebral effects to high plasma phenylalanine concentrations. |
format | Online Article Text |
id | pubmed-6893397 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-68933972019-12-23 Untreated PKU Patients without Intellectual Disability: What Do They Teach Us? van Vliet, Danique van Wegberg, Annemiek M.J. Ahring, Kirsten Bik-Multanowski, Miroslaw Casas, Kari Didycz, Bozena Djordjevic, Maja Hertecant, Jozef L. Leuzzi, Vincenzo Mathisen, Per Nardecchia, Francesca Powell, Kimberly K. Rutsch, Frank Stojiljkovic, Maja Trefz, Fritz K. Usurelu, Natalia Wilson, Callum van Karnebeek, Clara D. Hanley, William B. van Spronsen, Francjan J. Nutrients Article Phenylketonuria (PKU) management is aimed at preventing neurocognitive and psychosocial dysfunction by keeping plasma phenylalanine concentrations within the recommended target range. It can be questioned, however, whether universal plasma phenylalanine target levels would result in optimal neurocognitive outcomes for all patients, as similar plasma phenylalanine concentrations do not seem to have the same consequences to the brain for each PKU individual. To better understand the inter-individual differences in brain vulnerability to high plasma phenylalanine concentrations, we aimed to identify untreated and/or late-diagnosed PKU patients with near-normal outcome, despite high plasma phenylalanine concentrations, who are still alive. In total, we identified 16 such cases. While intellectual functioning in these patients was relatively unaffected, they often did present other neurological, psychological, and behavioral problems. Thereby, these “unusual” PKU patients show that the classical symptomatology of untreated or late-treated PKU may have to be rewritten. Moreover, these cases show that a lack of intellectual dysfunction despite high plasma phenylalanine concentrations does not necessarily imply that these high phenylalanine concentrations have not been toxic to the brain. Also, these cases may suggest that different mechanisms are involved in PKU pathophysiology, of which the relative importance seems to differ between patients and possibly also with increasing age. Further research should aim to better distinguish PKU patients with respect to their cerebral effects to high plasma phenylalanine concentrations. MDPI 2019-10-25 /pmc/articles/PMC6893397/ /pubmed/31731404 http://dx.doi.org/10.3390/nu11112572 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article van Vliet, Danique van Wegberg, Annemiek M.J. Ahring, Kirsten Bik-Multanowski, Miroslaw Casas, Kari Didycz, Bozena Djordjevic, Maja Hertecant, Jozef L. Leuzzi, Vincenzo Mathisen, Per Nardecchia, Francesca Powell, Kimberly K. Rutsch, Frank Stojiljkovic, Maja Trefz, Fritz K. Usurelu, Natalia Wilson, Callum van Karnebeek, Clara D. Hanley, William B. van Spronsen, Francjan J. Untreated PKU Patients without Intellectual Disability: What Do They Teach Us? |
title | Untreated PKU Patients without Intellectual Disability: What Do They Teach Us? |
title_full | Untreated PKU Patients without Intellectual Disability: What Do They Teach Us? |
title_fullStr | Untreated PKU Patients without Intellectual Disability: What Do They Teach Us? |
title_full_unstemmed | Untreated PKU Patients without Intellectual Disability: What Do They Teach Us? |
title_short | Untreated PKU Patients without Intellectual Disability: What Do They Teach Us? |
title_sort | untreated pku patients without intellectual disability: what do they teach us? |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6893397/ https://www.ncbi.nlm.nih.gov/pubmed/31731404 http://dx.doi.org/10.3390/nu11112572 |
work_keys_str_mv | AT vanvlietdanique untreatedpkupatientswithoutintellectualdisabilitywhatdotheyteachus AT vanwegbergannemiekmj untreatedpkupatientswithoutintellectualdisabilitywhatdotheyteachus AT ahringkirsten untreatedpkupatientswithoutintellectualdisabilitywhatdotheyteachus AT bikmultanowskimiroslaw untreatedpkupatientswithoutintellectualdisabilitywhatdotheyteachus AT casaskari untreatedpkupatientswithoutintellectualdisabilitywhatdotheyteachus AT didyczbozena untreatedpkupatientswithoutintellectualdisabilitywhatdotheyteachus AT djordjevicmaja untreatedpkupatientswithoutintellectualdisabilitywhatdotheyteachus AT hertecantjozefl untreatedpkupatientswithoutintellectualdisabilitywhatdotheyteachus AT leuzzivincenzo untreatedpkupatientswithoutintellectualdisabilitywhatdotheyteachus AT mathisenper untreatedpkupatientswithoutintellectualdisabilitywhatdotheyteachus AT nardecchiafrancesca untreatedpkupatientswithoutintellectualdisabilitywhatdotheyteachus AT powellkimberlyk untreatedpkupatientswithoutintellectualdisabilitywhatdotheyteachus AT rutschfrank untreatedpkupatientswithoutintellectualdisabilitywhatdotheyteachus AT stojiljkovicmaja untreatedpkupatientswithoutintellectualdisabilitywhatdotheyteachus AT trefzfritzk untreatedpkupatientswithoutintellectualdisabilitywhatdotheyteachus AT usurelunatalia untreatedpkupatientswithoutintellectualdisabilitywhatdotheyteachus AT wilsoncallum untreatedpkupatientswithoutintellectualdisabilitywhatdotheyteachus AT vankarnebeekclarad untreatedpkupatientswithoutintellectualdisabilitywhatdotheyteachus AT hanleywilliamb untreatedpkupatientswithoutintellectualdisabilitywhatdotheyteachus AT vanspronsenfrancjanj untreatedpkupatientswithoutintellectualdisabilitywhatdotheyteachus |